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Abstract
Background: Abdominal scars pose a challenge in magnetic resonance-guided high-intensity focused ultrasound
(MR-HIFU) therapies, limiting patient selection and increasing the risk of skin burns. Especially, scars arising from
longitudinal incisions are problematic as they usually lie medially at the lower abdomen where the ultrasound
beam has to go through. Volumetric sonication has been shown to efficiently enlarge the ablated volume per
sonication, but they nevertheless require more thermal energy to be deposited per sonication which increases
the temperature in the near-field area located between the transducer and the target region.
Case presentation: The scar patch was used in three patients undergoing MR-HIFU ablation of fibroids using
volumetric technique, one with transverse incision and the other two with longitudinal incision. No severe
adverse effects were observed. The relative shrinkage of the fibroid of these patients at 6-month follow-up
were 67, 78, and 59 %, respectively.
Conclusions: Our preliminary experience suggests that the use of scar patch on MR-HIFU ablation of fibroids using
volumetric technique provides an effective treatment option for patients who were previously excluded from
MR-HIFU treatment due to the abdominal scars.
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Background
Magnetic resonance-guided high-intensity focused ultra-
sound (MR-HIFU) which allows for 3D treatment plan-
ning and feedback of temperature deposition in the area
to be treated is an emerging therapy technique which
uses focused ultrasound to heat and coagulate tissue
deep within the body, with minimal damage to surroun-
ding tissues. A number of studies have shown the clinical
effectiveness of MR-HIFU for uterine fibroid treatment
[1–8]. The conventional approach is performed by itera-
tive sonication of a single focal point with each sonication
followed by a cooling period. However, with this approach,
a relatively large portion of the delivered energy is lost via
diffusion of heat out of the small targeted region, and long
treatment duration is required. Recently, a new volumetric
ablation technique [9–11] has been introduced. This
technique is able to utilize the outwards-diffused heat
energy, while inducing relatively large ablation zones with
an axial diameter of 4–16 mm since the focus of the
ultrasound beam is electronically steered along a trajec-
tory comprising of multiple outward-moving concentric
circles. However, the energy deposition per sonication in
this technique is higher than in the conventional one.
Since all biological tissues absorb ultrasound energy to
various extents, the increase in deposited energy might
inevitably lead to higher temperature rise in the near field
of the ultrasound beam path [12, 13].
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The presence of abdominal scars may limit the access to
the target area and increase the risk of near field damage
during the MR-HIFU therapy. Until recently, the presence
of scars in the ultrasound beam path was considered to be
a contraindication for MR-HIFU in patients with uterine
fibroids, as their presence can induce local skin heating
leading to skin burns [3, 14–16]. At least one case with
full-thickness skin burn at the location of previous laparo-
scopic scar necessitating a referral for plastic surgery has
been reported [17, 18].
Zaher et al. [17] described a mitigation technique which
helps to visualize the location of the scar and therefore
facilitates therapy planning where the beam path does not
go through the scar. This however is not practical with
patients having longitudinal incision, as it is very difficult
to avoid sonications through the area if the scar is located
medially at the abdomen. Gorny et al. [19] proposed the
use of acoustic patches on the skin to reflect the ultra-
sound energy from the scar. Yoon et al. [20] confirmed
that the use of these scar patches can be a viable solution.
In their study among 20 patients, about 57 % of the soni-
cations in each treatment were through the scar patch,
and only in one of the treatments (5 %), it was possible to
tilt the beam to totally bypass the scar. Although two
patients had minor red spots on the skin surface after the
treatment and three other patients had slight hyperemic
changes in the abdominal muscle, no serious adverse
events were reported.
The purpose of this study is to assess the safety and
technical feasibility of scar patch usage on MR-HIFU
ablation of fibroids using volumetric technique. To the
best of the authors’ knowledge, this is the first publication
to report the use of the scar patches during MR-HIFU
therapy on uterine fibroids using volumetric technique.
Case presentation
Materials and methods
As a part China Clinical Trial for Therapeutic MR-HIFU
Ablation of Uterine Fibroids (sponsored by Philips
Healthcare, clinicaltrials.gov identifier NCT01588899), a
total of 58 MR-HIFU therapies were conducted at our
institute. In three patients, the scar patch, in accordance
with manufacturer’s instructions, labeling, and trial proto-
col, was used to prevent local skin heating which might lead
to skin burns. All therapies were conducted using extracor-
poreal MRI-HIFU system (Sonalleve V2 MR-HIFU system)
in combination with 3.0 T MR scanner (Achieva, Philips
Healthcare, Amsterdam, The Netherlands). Three patients
in our case report, one with transverse incision, the other
two with longitudinal incision, received the same imaging
protocols and treatment procedures. As shown in Table 1,
the imaging protocols for screening, HIFU treatment, and
6-month follow-up after HIFU therapy are mainly including
3D sagittal T2-weighted turbo spin echo (T2W-TSE, fast
field echo (FFE) and a contrast-enhanced T1-weighted
turbo spin echo (T1W-TSE). The MR sequence used for
temperature mapping is an RF-spoiled segmented echo
planar imaging sequence: EPI factor = 11, repetition time
TR = 37 ms, echo time TE = 19.5 ms, 121-binomial water-
selective excitation.
Depilation of the lower abdomen was conducted 1 day
before the therapy, and Foley catheter was inserted just
before the treatment. On the treatment day, patients were
placed in a prone position before acquiring the pretreat-
ment MR images for HIFU therapy planning. Then, the
treatment cells were placed on the T2W planning images
by carefully considering safety margins from the borders
of the treatment cells to capsule of the fibroid and the
critical organs such as sacral bone which were 1.5 and
Table 1 Imaging protocols




Matrix size TA (s)
Screening 3D T2 TSE Uterine fibroid Sagittal 1500 165 90 3 250 × 250 176 × 173 177
FFE Scar visualization Coronal 3.4 1.74 10 2 200 × 200 172 × 173 79
CE-T1 TSE* Uterine fibroid Coronal 5.5 2.7 12 2.5 250 × 250 192 × 192 130
Treatment 3D T2 TSE Treatment
planning
Sagittal 1550 150 90 1.6 250 × 250 176 × 173 124.9
FFE Scar and scar
patch
Coronal 3.4 1.74 10 2 200 × 200 172 × 173 79
EPI Temperature
mapping
Coronal, sagittal 37 19.5 19 7 400 × 400 160 × 160 2.9
CE-T1 TSE* Non-perfused
volume
Coronal 5.5 2.7 12 2.5 250 × 250 192 × 192 130
6-month follow-up 3D T2 TSE Uterine fibroid Sagittal 1487 165 90 2.5 250 × 250 176 × 173 140
CE-T1 TSE* Non-perfused
volume
Coronal 5.5 2.7 12 2.5 250 × 250 192 × 192 130
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4 cm, respectively. When necessary, urinary bladder filling
with normal saline solution and/or rectal filling with US
gel was performed to move the path of the sonication
beam out of the scar area or to displace small bowel loops.
The binary feedback technique [9] was applied to per-
form volumetric ablation. The ablation zone (i.e., treatment
cell) is ellipsoidal in shape and can be chosen as 4, 8, 12,
14, or 16 mm in axial dimension and 10, 20, 30, 35, or
40 mm in longitudinal dimension, respectively. Sonication
power level (140–300 W) was determined based on the
results of an initial test sonication with low power (60 W)
and adjusted in an iterative manner based on the results of
the previous sonications. Patients were asked to press a
hand-held “stop button” if they experienced intolerable
pain, and their movements and organ motions were moni-
tored during the treatment by placing multiple fiducial
markers at the boundary of the uterus and the pelvic bones
on 3D T2W planning data. HIFU ablation was monitored
during the sonications with multi-plane MR thermometry
utilizing the proton resonance shift technique [21]. Three
coronal planes and one sagittal plane through the target
area together with one coronal plane positioned over the
abdominal muscle were utilized.
The scar patches (QuickCover US Protective Cover)
used in this study were made out of polyethylene foam
with the size of 8 mm× 120 mm. The back of the sheet is
self-adhesive to ensure that the patch does not move
during the therapy. Once attached on the skin, the patch
creates an ultrasound-reflecting air layer, thus preventing
the ultrasound energy from reaching the scar tissue
immediately behind the patch. Patches were clearly visible




A 41-year-old woman presented with symptoms of men-
orrhagia, pelvic pressure, and urinary frequency, with ute-
rine fibroid symptom severity score (SSS) of 24. MRI
study revealed two fibroids, one of which was chosen as a
clinical target based on the symptom profile. Patient had a
transverse incision scar on her lower abdomen (Fig 1a, b).
Targeted fibroid was intramural, located at the anterior
wall, and had a volume of 120 ml (Fig 1c). Fibroid was
homogenous and iso-intense to muscle on the T1W
images, hypo-intense to muscle on the T2W images, and
demonstrated moderate and homogeneous enhancement
on gadolinium-enhanced T1W image.
The treatment time from first to last sonication was
165 min. Good temperature rise was seen clearly at the
focal area on sagittal temperature slice (Fig 1d), indicating
that presence of the scar patch within the beam path did
not affect the focus quality negatively. No obvious heating
could be seen at the scar location. Delayed contrast-
enhanced T1W images collected immediately after abla-
tion showed that the immediate non-perfused volume
(NPV) was 44 % (Fig 1e). Following the treatment, slight
reddening of the skin at the upper abdomen, away from
the scar patch area was observed. However, no areas of
abnormal enhancement within the subcutaneous tissue or
Fig. 1 A 41-year-old woman who had a transverse incision scar presented with symptoms of menorrhagia, pelvic pressure, and urinary frequency
was treated with MRI-guided high-intensity focused ultrasound ablation using scar patch. a Scar scan showing the orientation of the scar within
the abdominal fat layer (scar location identified with white arrows). b Scar scan showing the air-containing scar patch at the patient’s skin. c T2w
planning image acquired prior to the therapy. d PRF Thermometry scan acquired during one of the sonications. e T1w gadolinium-enhanced
image acquired immediately after the therapy showing the induced necrosis. f T2w planning image at 6-month follow-up
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the regions of the scar were identified. The volume and
shrinkage of the fibroid at 6 months follow-up were 39 ml
and 67 %, respectively (Fig 1f). The patient reported that
urinary frequency had completely resolved and the patients’
SSS reduced to 12.
Case 2
A 49-year-old woman presented with symptoms of men-
orrhagia, pelvic pressure, and urinary frequency, with SSS
of 22. MRI study revealed multiple fibroids, one of which
was chosen as a clinical target based on the symptom
profile. Patient had a longitudinal incision scar on her
lower abdomen (Fig 2a, b). Targeted fibroid was located in
the anterior wall and had a volume of 65 ml (Fig 2c).
Fibroid was mostly homogenous and iso-intense to muscle
on the T1W images and hypo-intense to muscle on the
T2W images. T2W images showed also hyper-intense
fascia within the fibroid.
The treatment time from first to last sonication was
112 min. Good temperature rise was seen clearly at the
focal area on sagittal temperature slice (Fig 2d), and no
obvious heating could be seen at the scar location. No skin
reddening or other near field related adverse effects were
observed. The NPV immediately after treatment was 41 %
(Fig 2e). The volume and shrinkage of the targeted fibroid
at 6-month follow-up were 14 ml and 78 % (Fig 2f). The
SSS reduced to 13 at 6-month follow-up.
Case 3
A 43-year-old woman presented with menorrhagia, with
SSS of 14. MRI study revealed longitudinal incision on her
lower abdomen (Fig 3a, b) and multiple fibroids, one of
which was chosen as a clinical target based on the symp-
tom profile. Targeted fibroid was located in the anterior
wall and had a volume of 71 ml (Fig 3c). The fibroid was
mostly homogenous and iso-intense to muscle on the
T1W images and hypo-intense to muscle on the T2W im-
ages with hyper-intense linear separation on T2W images.
The treatment time from first to last sonication was
101 min. Good temperature rise was seen clearly at the
focal area on sagittal temperature slice (Fig 3d), and no
obvious heating could be seen at the scar location. The
NPV immediately after treatment was 80 % (Fig 3e). The
volume and shrinkage of the fibroid at 6-month follow-up
were 29 ml and 59 %, respectively (Fig 3f ). The SSS at
6-month follow-up was 12.
Discussion
In MR-HIFU treatments, the radiologists and/or gyneco-
logists are trying to avoid passing US energy through the
scar by tilting the beam around it to reduce risk of near-
field damage. Abdominal scars pose a challenge in MR-
HIFU therapies, possibly limiting patient selection and
increasing the risk of skin burns. Yoon et al. [20] reported
the use of scar patches in MR-HIFU treatment of uterine
fibroids (19 patients with transverse incision and 1 patient
with longitudinal incision) with point-by-point technique
by showing low incidence of minor adverse events without
severe adverse events comparing with previous studies
without a scar patch [3, 5, 22, 23].
In our report with volumetric technique, there were
three patients, one with transverse incision, the other two
Fig. 2 A 49-year-old woman who had a longitudinal incision presented with symptoms of menorrhagia, pelvic pressure, and urinary frequency
was treated with MRI-guided high-intensity focused ultrasound ablation using scar patch. a Scar scan showing the orientation of the scar within
the abdominal fat layer (scar location identified with white arrows). b Scar scan showing the air-containing scar patch at the patient’s skin. c T2w
planning image acquired prior to the therapy. d PRF Thermometry scan acquired during one of the sonications. e T1w gadolinium-enhanced
image acquired immediately after the therapy showing the induced necrosis. f T2w planning image at 6-month follow-up
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with longitudinal incision, all of whom received the same
imaging protocols and treatment procedures. In sonica-
tions where beam path went through a scar, temperature
images were followed carefully to detect any unwanted
heating in the scar region. Sufficient cooling times were
observed between sonications to reduce the possibility of
damage due to accumulated heating. Good communica-
tion with the patient was ensured to obtain immediate
information of any abnormal sensations. Volumetric MR-
HIFU ablation therapy was technically successful in all
three cases. Focus quality was not visibly affected by the
presence of the scar patch, which indicates that the scar
patch did not significantly reduce the efficacy of energy
delivery to target, even though it blocks a small portion of
the beam path. NPVs obtained in these three therapies
were 44, 41, and 80 %, while 6-month fibroid shrinkages
were 67, 78, and 59 %, respectively, indicating that clinical
effectiveness is not hampered by the presence of the scar
patch either. Reduced symptom severity score for each
patient at 6-month follow-up also demonstrated the relief
of subjective symptoms. In addition, there was no thermal
injury of the abdominal muscle or subcutaneous fat layer.
Our study has some limitations. First, given all the
fibroids enrolled were Funaki type 1 with hypo-vascularity
[24], further research should be conducted to demonstrate
the feasibility of using scar patches when the volumetric
method is applied to fibroids of types 2 and 3, which are
more vascular and typically require higher sonication
energies. Second, we currently report results of only three
cases. A prospective study with larger patient population
is still needed.
Conclusion
In conclusion, our preliminary experience suggests that
the use of scar patch on MR-HIFU ablation of fibroids
using volumetric technique provides an effective treat-
ment option for patients who were previously excluded
from MR-HIFU treatment due to the abdominal scars.
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